Literature DB >> 15160244

[Biologicals: a new therapeutic approach for inflammatory diseases].

C E Antoni1, B Manger.   

Abstract

The pathogenesis of inflammatory diseases is determined by a malfunction of the immune system. Up to now therapies have not been able to cure but to interfere in a more or less specific way with the immune function. The great increase of knowledge in immunology made it possible to develop new medications, which alter the immune system in a specific way. The advantage is the relative simple way of developing new medications by using monoclonal antibodies against specific antigens and testing the hypothesis in animal model and in small but clear phase II trials. Biologicals are similar or identical to human proteins and rarely have side effects, which exceed their interference with the immune system. Because of the clinical success of anti-TNF-therapies and the increased knowledge about immune mechanisms, biologicals are now used in various fields of medicine. This paper reviews data from biologicals that are either already approved or in an advanced stage of clinical testing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160244     DOI: 10.1007/s00108-004-1225-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

Authors:  U Chaudhari; P Romano; L D Mulcahy; L T Dooley; D G Baker; A B Gottlieb
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

3.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Authors:  Gerald G Krueger; Kim A Papp; Dow B Stough; Keith H Loven; Wayne P Gulliver; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

4.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

Authors:  Kenneth B Gordon; Kim A Papp; Tiffani K Hamilton; Patricia A Walicke; Wolfgang Dummer; Nicole Li; Brian W Bresnahan; Alan Menter
Journal:  JAMA       Date:  2003-12-17       Impact factor: 56.272

7.  The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.

Authors:  Gail M Gauvreau; Allan B Becker; Louis-Philippe Boulet; Jamila Chakir; Robert B Fick; William L Greene; Kieran J Killian; Paul M O'byrne; John K Reid; Donald W Cockcroft
Journal:  J Allergy Clin Immunol       Date:  2003-08       Impact factor: 10.793

Review 8.  Antibody therapy for rheumatoid arthritis.

Authors:  Peter C Taylor
Journal:  Curr Opin Pharmacol       Date:  2003-06       Impact factor: 5.547

9.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

Authors:  Mark Lebwohl; Stephen K Tyring; Tiffani K Hamilton; Darryl Toth; Scott Glazer; Naji H Tawfik; Patricia Walicke; Wolfgang Dummer; Xiaolin Wang; Marvin R Garovoy; David Pariser
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
View more
  1 in total

1.  [Are "biologics" in the treatment of rheumatoid arthritis really cost effective?].

Authors:  U Müller-Ladner
Journal:  Internist (Berl)       Date:  2004-12       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.